196811-66-2

Basic information

• Product Name: 4-THIOCARBAMOYL-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: 4-THIOCARBAMOYL-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;4-(tert-Butoxycarbonyl)piperazine-1-thiocarboxamide;tert-butyl 4-carbamothioylpiperazine-1-carboxylate;1-Boc-4-CarbaMothioylpiperazine;1-Piperazinecarboxylic acid, 4-(aMinothioxoMethyl)-, 1,1-diMethylethyl ester;1-Piperazinecarboxylic ac...;4-(tert-Butoxycarbonyl)piperazine-1-
• CAS NO: 196811-66-2
• Molecular Formula: C₁₀H₁₉N₃O₂S
• Molecular Weight: 245.34
• Mol File: 196811-66-2.mol

Chemical Properties

• Boiling Point: 354.7°C at 760 mmHg
• Flash Point: 168.3°C
• Appearance: /
• Density: 1.214g/cm³
• Vapor Pressure: 3.29E-05mmHg at 25°C
• Refractive Index: 1.564
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 16.15±0.20(Predicted)
• CAS DataBase Reference: 4-THIOCARBAMOYL-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-THIOCARBAMOYL-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(196811-66-2)
• EPA Substance Registry System: 4-THIOCARBAMOYL-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(196811-66-2)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 196811-66-2(Hazardous Substances Data)

Usage

Uses

Due to the limited research on 4-Thiocarbamoyl-Piperazine-1-Carboxylic acid tert-butyl ester, its specific applications are not well-defined. However, based on its chemical structure, it may have potential uses in the following areas:
Used in Pharmaceutical Industry:
4-Thiocarbamoyl-Piperazine-1-Carboxylic acid tert-butyl ester could be used as a pharmaceutical compound for its potential central nervous system stimulant effects or antimicrobial properties, as many piperazine derivatives exhibit these characteristics.
Used in Organic Synthesis:
In the field of organic synthesis, 4-Thiocarbamoyl-Piperazine-1-Carboxylic acid tert-butyl ester might serve as a reagent or intermediate due to its highly reactive and versatile functional groups, which could be utilized in the synthesis of more complex molecules.

InChI:InChI=1/C10H19N3O2S/c1-10(2,3)15-9(14)13-6-4-12(5-7-13)8(11)16/h4-7H2,1-3H3,(H2,11,16)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 1018148-64-5 tert-butyl 4-(benzoylcarbamothioyl)piperazine-1-carboxylate 
• 88681-68-9 di(1H-imidazol-2-yl)methanethione 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 6160-65-2 1,1'-Thiocarbonyldiimidazole 

Downstream Products

• 668484-34-2 C₁₈H₂₂BrN₃O₂S 
• 69389-14-6 4-phenyl-2-(piperazin-1-yl)thiazole 
• 867065-53-0 4-(4-ethoxycarbonylthiazol-2-yl)piperazine-1-carboxylic acid tert-butyl ester 
• 887624-04-6 tert-butyl 4-(4-phenylthiazol-2-yl)piperazine-1-carboxylate 
• 105653-53-0 ethyl 2-(piperazin-1-yl)thiazole-4-carboxylate hydrochloride 
• 1114770-68-1 C₂₀H₂₇N₃O₃S 

Relevant articles and documents

Efficient Synthesis of Benzothiazinone Analogues with Activity against Intracellular Mycobacterium tuberculosis

8-Nitrobenzothiazinones (BTZs) are a promising class of antimycobacterial agents currently under investigation in clinical trials. Starting from thiourea derivatives, a new synthetic pathway to BTZs was established. It allows the formation of the thiazinone ring system in one synthetic step and is applicable for preparation of a wide variety of BTZ analogues. The synthetic procedure furthermore facilitates the replacement of the sulphur atom in the thiazinone ring system by oxygen or nitrogen to afford the analogous benzoxazinone and quinazolinone systems. 36 BTZ analogues were prepared and tested in luminescence-based assays for in vitro activity against Mycobacterium tuberculosis (Mtb) using the microdilution broth method and a high-throughput macrophage infection assay.

The optimization of xanthine derivatives leading to HBK001 hydrochloride as a potent dual ligand targeting DPP-IV and GPR119

A series of xanthine compounds derived from the previous hit 20i with modification on the terminal side chain was discovered through ring formation strategy. Systematic optimization of the compounds with rigid heterocycles in the hydrophobic side chain led to the new lead compound HBK001 (21h) with the improved DPP-IV inhibition and moderate GPR119 agonism activity in vitro. As a continuing work to further study the PK and PD profiles, 21h and its hydrochloride (22) were synthesized on grams scale and evaluated on the ADME/T and oral glucose tolerance test (OGTT) in ICR mice. Compound 22 showed the improved bioavailability and blood glucose-lowering effect in vivo compared to its free base 21h probably attributed to its improved solubility and permeability. The preliminary toxicity studies on compound 22 exhibited that the result of mini-Ames was negative and the preliminary acute toxicity LD50 in mice was above 1.5 g/kg, while it showed moderate inhibition on hERG channel with IC50 4.9 μM maybe due to its high lipophilicity. These findings will be useful for the future drug design for more potent and safer dual ligand targeting DPP-IV and GPR119 for the treatment of diabetes.

ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES

The invention relates to acid addition salts of piperazine derivatives, as well as solid forms, such as polymorphic forms, thereof, which are useful as pharmaceutical ingredients and in particular as glycosidase inhibitors.

GLYCOSIDASE INHIBITORS

Compounds of formula (I) wherein A, R, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK AND THEIR PREPARATION AND USE IN THE TREATMENT OF CANCER, INFLAMMATION AND AUTOIMMUNE DISEASE

Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).

AZOCYCLIC INHIBITORS OF FATTY ACID AMIDE HYDROLASE

Disclosed are compounds of Formula 1, including all stereoisomers, N oxides, and salts thereof, wherein A, W, X, G, R1, R2, R3, R4, m and n are as defined in the disclosure. Also disclosed are pharmaceutical compositions containing the compounds of Formula 1 and methods for treating a disease or condition mediated by fatty acid amide hydrolase activity comprising applying a therapeutically effective amount of a compound or a composition of the invention

N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES

This invention provides thiazolylpiperazine derivatives, and N-sulfonyl heterocyclic derivatives including phenyl- and benzyl-thiazolylpiperidine derivatives, and pharmaceutically acceptable salts thereof, which are useful active ingredients for administration in a method for the treatment of an α-synucleopathy such as Parkinson's disease, diffuse Lewy body disease, traumatic brain injury, amyotrophic lateral sclerosis, Niemann-Pick disease, Hallervorden-Spatz syndrome, Down syndrome, neuroaxonal dystrophy, multiple system atrophy and Alzheimer's disease. This invention also provides methods for making such derivatives, and pharmaceutical compositions including such derivatives together with pharmaceutically acceptable excipients.

FUNGICIDAL MIXTURES

Disclosed is a fungicidal composition comprising (a) at least one compound selected from the compounds of Formula 1 N-oxides, and salts thereof, wherein R1, R2, A, G, W, Z1, X, J, and n are as defined in the disclosure, and (b) at least one additional fungicidal compound. Also disclosed is a method for controlling plant diseases caused by fungal plant pathogens comprising applying to the plant or portion thereof, or to the plant seed, a fungicidally effective amount of the aforesaid composition. Also disclosed is a composition comprising component (a) of aforesaid composition and at least one insecticide. Also disclosed are compounds of Formula 1A, 1B and 1C, wherein R1, R2, A, G, W, Z1, X, J, n, Z3, M and J1 are as defined in the disclosure.

Design and synthesis of DPP-IV inhibitors lacking the electrophilic nitrile group

A series of (4β-substituted)-l-prolylpyrrolidine analogs lacking the electrophilic nitrile function were synthesized and their dipeptidyl peptidase IV (DPP-IV) inhibitory activity and duration of ex vivo activity were evaluated. Structural optimization of a N-(3-phenyl-1,2,4-thiadiazol-5-yl)piperazine analog 8, which was found by high-speed analog synthesis, was carried out to improve the potency and duration of action. A representative compound 26 was evaluated to assess its effect on the plasma glucose level after the oGTT (oral glucose tolerance test) in normal rats. Structure-activity relationships (SAR) are also presented.

ELECTRONIC COMPONENT HAVING FLEXIBLE PRINTED CIRCUIT BOARD TECHNOLOGY

The invention relates to an electronic component (1) having a housing comprising at least one base plate (3), a housing cover, and at least two electronic connections (5) between substrates (7) disposed in the interior of the housing and components located outside the housing in the form of printed circuit boards, which can be at least partially fixed on the base plate (3), wherein at least one first partially flexible printed circuit board (5a) and a second printed circuit board (5b) are configured such that they overlap at least in one region (6) in the assembled state. The invention further relates to a method for the production of such an electronic component.